XTLB | XTL Biopharmaceuticals Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8100 - 2.0000
52 Week Range	0.7700 - 4.99
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	13,684
Average Volume	45,424
Shares Outstanding	12,543,400
Market Cap	25,086,800
Sector	Healthcare
Industry	Biotechnology
IPO Date	2005-09-01

Valuation
Profitability
Growth
Health
P/E Ratio	-10.00
Forward P/E Ratio	N/A
EPS	-0.20
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	Israel
Website	XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

XTLB's peers: BRTX, CANF, BNTC, XBIO, PRPH, BVXV, BOSC

*Chart delayed

Analyzing fundamentals for XTLB we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see XTLB Fundamentals page.

Watching at XTLB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on XTLB Technicals page.